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Many patients with asthma remain symptomatic with impaired airway function on inhaled
steroids. This study investigates the relationship between the clinical effect seen in
response to additional treatment and the effect on airway inflammatory indices.
Seventy-five adult asthmatic patients, incompletely controlled on 800mcg budesonide/
day, were randomised following a 4 week run-in period, to a double-blind, multi-centre
controlled clinical trial of doubling inhaled corticosteroid (budesonide 1600mcg/day) or
adding 10mg montelukast for 12 weeks. Induced sputum was collected at baseline and end
of treatment and analysed for eosinophil and neutrophil percentages, leukotrienes C4, D4
and E4, IL-8, Eosinophil Cationic Protein (ECP) and histamine.
Sputum evidence of inflammation (X2:0% eosinophils) was seen in only 29% of these
patients and the percentage of eosinophils and other markers of airway inflammation didElsevier Ltd. All rights reserved.
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.com (H. Tate).
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Asthma: Sptum cells and mediators 1653not change over the study period in either treatment group. There were significant
improvements in am PEF (montelukast: 31.7 L/min, budesonide: 32.3 L/min) and quality of
life with both treatments.
We conclude that while both treatments showed similar improvements in lung function and
quality of life, there was no evidence from these sputum markers measured that the
effects were mediated via a reduction in airway inflammation or that the level of pre-
treatment markers was associated with outcome.
& 2007 Elsevier Ltd. All rights reserved.Introduction
In mild to moderate asthmatic patients taking bronchodila-
tors only, numerous studies have demonstrated the presence
of airway inflammation.1–6 In biopsy studies there is an
increase in eosinophils and CD4 positive T lymphocytes,
thickening of the basement membrane and epithelial
disruption.1 In sputum the characteristic finding in sympto-
matic patients on bronchodilators is of sputum eosinophi-
lia.2–6 When patients are treated with inhaled
corticosteroids many of these abnormalities improve6 but
symptoms can continue in up to 50% of patients.7 The extent
to which these residual symptoms are causally linked to
eosinophilic inflammation is unclear, because the inflamma-
tion was not measured.
There is a range of treatment choices in symptomatic
patients on inhaled steroids including increasing the dose
of inhaled corticosteroids, the addition of long-acting
inhaled bronchodilator, the addition of leukotriene receptor
antagonist or the addition of slow-release theophyllines.7
There is continuing debate about which of these is the
preferred option. Part of this debate is fuelled by differing
views regarding the relative importance of the different
modes of action of these agents. Inhaled corticosteroids’
major mode of action is to decrease airway inflammation.
Long-acting inhaled b2-agonists primarily relax airway
smooth muscle, and there is little compelling evidence of
anti-inflammatory effect of these agents in chronic asthma.8
The leukotriene receptor antagonists relax airway smooth
muscle by antagonising the effect of broncho-constrictor
cysteinyl leukotrienes but they also have an anti-inflamma-
tory effect, distinct from that of inhaled corticosteroids.9
There are only a limited number of studies that have
investigated the additional anti-inflammatory effects of
different strategies in patients already taking inhaled
corticosteroids.
There is evidence from a number of placebo controlled
studies that the addition of a leukotriene antagonist, in
patients inadequately controlled on inhaled corticosteroids,
produces improvements in pulmonary function, symptoms,
b2-agonist use and asthma exacerbations,
10,11 although
whether these effects are associated with anti-inflammatory
effects is unknown. We investigated in symptomatic patients
with impaired airway function on moderate doses of inhaled
steroid (budesonide 800mcg/day) the effect of the addition
of a leukotriene receptor antagonist (montelukast 10mg/
day) versus doubling the dose of inhaled corticosteroids and
measured airway inflammation. We used identical inclusion
and exclusion criteria and an identical protocol to a larger
study12 but added measurement of sputum markers ofinflammation at baseline and end of treatment to provide an
insight into the effect.
Methods
Subjects
The study design was identical to that of the larger clinical
study.12 Subjects were non-smokers aged 15–70 years with
41 year history of asthma symptoms. Their current
treatment was inhaled steroids (600–1200mcg/day budeso-
nide or equivalent) and b2-agonist only. Their bronchodilator
reversibility was X12% ðFEV1Þ or X15% (peak expiratory
flow, PEF) and they had 450% predicted FEV1=PEF. Despite
treatment, subjects remained symptomatic during the last 2
weeks of the 4 week run-in period, as assessed by a symptom
diary and daily b2-agonist use (on average at least one puff
per day). Exclusions included any other pulmonary disorder,
emergency treatment for asthma within 1 month, hospita-
lisation within 2 months or respiratory tract infection within
3 weeks.
Study design
The study was a multi-centre (four centres in the UK and two
centres in Canada), double-blind, parallel group randomised
controlled trial. Inhaled budesonide (800mcg/day) was
given during the 4 week run-in period, following which 75
patients were randomised to receive either 800mcg
budesonide via Turbuhaler plus 10mg montelukast daily or
1600mcg budesonide plus placebo for the 12 week treat-
ment period. Induced sputum samples were taken at
baseline and after the 12 week treatment period. Daily
diary cards were used to record symptoms,13 PEF and b2-
agonist use throughout the 16 weeks of the study period.
Asthma-specific quality of life questionnaire14 was com-
pleted at baseline and end of treatment. Compliance was
assessed from both the diary card and the pill count.
Induction and processing of sputum was conducted at
each centre using methods described elsewhere.5 Differ-
ential counts were performed in each country (Glenfield
Hospital, UK; St. Joseph’s Hospital, Canada). Histamine,
cysteinyl leukotrienes and IL-8 were measured by ELISA, ECP
by fluoroenzymeimmunassay at Glenfield Hospital using
methods described previously.15
The primary endpoint was change from baseline in sputum
eosinophil percentage. Secondary endpoints included other
sputum inflammatory markers, percentage change from
baseline (last 10 days of the run-in period) in morning PEF
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asthma-specific quality of life and percentage of days with
asthma exacerbations (defined as: decrease in am PEF of
420%; am PEFo180 L=min; increase in b2-agonist use of
470%; increase in symptom score of 450% or an asthma
attack resulting in an unscheduled medical visit or corticos-
teroid tablets).
Adverse events were assessed for severity, duration and
study drug causality. The study received ethical review
committee approval. Patients gave written informed con-
sent.Statistical considerations
The analysis was primarily descriptive. Protocol violators,
identified before the study was unblinded, were excluded
from the main efficacy analyses. The primary efficacy
measurement was analysed non-parametrically, because of
the large proportion of zero counts; a 95% confidence
interval for the median difference between treatment
groups was estimated.16 Additional Poisson and negative-
binomial modelling was undertaken. Neutrophil percentages
were analysed parametrically using analysis of covariance
with model factors of country and treatment group and the
baseline value as a covariate. The country by treatment
interaction was assessed and omitted if not significant. A
95% confidence interval for the mean difference in change
from baseline between treatments was derived. All other
markers followed highly positively skewed distributions and
were transformed to logarithms prior to parametric analysis,
leading to a 95% confidence interval for the ratio of change
between groups. Secondary efficacy measurements: change
in morning PEF and asthma-specific quality of life were
assessed by analysis of covariance. The percentage of days
with asthma exacerbations followed a highly skewed pattern
and therefore was analysed non-parametrically. Graphical
methods and Spearmen’s correlation coefficients were used
to assess possible relationships between baseline eosinophil
counts and PEF and changes in eosinophil levels with
changes in PEF, within each treatment group.
Planned analysis included only patients with baseline
eosinophils X2%. During recruitment, few patients had
eosinophils X2% and the decision was made to include all
patients and perform a subgroup analysis on those X2%.
Little data were available on eosinophil counts when the
study was designed and the sample size was based on
precision considerations. Thirty patients per group would
ensure the between group comparison of change fromTable 1 Demography and baseline characteristics.
Montelukast + budeso
800 mg ðN ¼ 37Þ
Age (years) mean (SD) 41.5 (11.7)
Gender M:F 14:23
Height (cm) mean (SD) 167.6 (10.4)
AM average PEF1 (L/min) mean (SD) 436.6 (149.3)
% predicted FEV1 mean (SD) 74.1 (13.0)
Quality of life mean (SD) 4.9 (1.1)baseline was reasonably precise (the 95% confidence interval
would span a distance approximately equal to the standard
deviation unit).Results
Seventy-five patients were randomised (Table 1). Compli-
ance was over 98% for all drugs from the diary card and 77%
for montelukast and 84% for placebo from drug accounting.
One patient in the montelukast group was designated a
protocol violator because he took prednisolone. In the
budesonide group there were four protocol violators (two
violated the inclusion criteria, and two took prednisolone)
and one patient withdrew consent. Paired sputum eosinophil
values were available for 24 subjects in the montelukast
group and 28 in the double dose budesonide group.
The eosinophil percentages indicating the change for each
patient (paired data) are shown in Figs. 1A and B, for the
montelukast and double dose budesonide groups, respec-
tively. At baseline 15 out of the 52 patients for whom paired
eosinophil counts were available (six in the montelukast
group and nine in the double dose budesonide group) had no
detectable eosinophils and altogether 37 (17 in the
montelukast group and 20 in the double dose budesonide
group) had values lower than 2.0%. The distribution of
percentage eosinophils was highly skewed, the largest value
being 27% and the median 0.8%. The median sputum
eosinophil counts before and after montelukast were 1.4%
and 0.9%, respectively. The median sputum eosinophil
counts before and after double dose budesonide were 0.5%
and 0.7%. There were no significant changes over the
treatment period and the confidence interval for the median
difference between groups was 0:60 to 0:95%, indicating
that the groups were similar. The Poisson distribution and
negative binomial distributions did not fit the data well; the
overall estimates for the treatment group difference using
these models were in line with the conclusion of no
treatment difference seen from the non-parametric ap-
proach. A subgroup analysis of those patients with a baseline
value of 2% or over (seven in the montelukast group and
eight in the double dose budesonide group, see Fig. 1)
showed that the median sputum eosinophil count decreased
from 6.3% to 2.0% (95% CI of median change 7:0% to 21:3%)
with montelukast and from 8.7% to 1.6% (95% CI of median
change 7:3% to 5:3%) with double dose budesonide.
Other sputum cell and mediator results, before and after
treatment, are shown in Table 2. There were no within group
differences over the treatment period for either treatmentnide Budesonide 1600mg ðN ¼ 38Þ
45.0 (14.2)
20:18
169.9 (9.7)
449.7 (145.0)
73.6 (14.2)
4.9 (0.9)
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Figure 1 Graphs of individual sputum eosinophil counts (%) at baseline and end of treatment. Panel A: budesonide 800mgþ
montelukast 10mg group ðn ¼ 24Þ, Panel B: budesonide 1600mg group ðn ¼ 28Þ. Solid lines join observations in the same subject. The
heavy solid line joins the median values at the two time points.
Asthma: Sptum cells and mediators 1655group for any of the inflammatory markers. No differences
between treatment groups in change from baseline were
apparent—all confidence intervals include the null value (0
for mean/median for eosinophils, neutrophils, days with
asthma exacerbations and QoL and 1 for the ratios for other
markers).
The treatment effect on PEF over the study period is
shown in Fig. 2 (paired data). Morning PEF increased by
31.7 L/min (95% CI 10.8 to 52.6) in the montelukast group
and 32.3 L/min (95% CI 10.7 to 53.9) in the double dose
budesonide group (95% confidence interval for the differ-
ence between groups was 29:4 to 30:6 L=min). The median
percentage of days with asthma exacerbations (as defined
above) was similar in the two groups (see Table 2).
There was a clinically significant improvement in the
adjusted total asthma-specific quality of life score of 0.73
points (95% CI 0.46 to 1.00) with montelukast and 0.48
points (95% CI 0.20 to 0.77) with double dose budesonide.
There was no significant difference between treatment
groups ðp ¼ 0:21Þ.
Correlation plots showed no associations between base-
line sputum eosinophil count or change in sputum eosinophil
count and change in morning PEF in either treatment group
(Spearmen’s correlation coefficients were all less than 0.25,
associated p values were all greater than 0.2).
There were no serious adverse events. Twenty-eight
patients in the montelukast group (76%) and 33 (87%) in
the double budesonide group experienced minor adverse
events.Discussion
This study is one of the first to investigate the effect of anti-
asthmatic drugs on airway inflammation in patients already
taking inhaled corticosteroids. It was a large multi-centre
study with a total of 75 patients taking part. Our aim was to
investigate the effect of doubling the dose of inhaled
steroids or adding montelukast on sputum measures ofairway inflammation in patients taking inhaled corticoster-
oids and to see if there was any relationship between
changes in airway inflammation and clinical outcomes. The
study was designed to give a mechanistic insight into the
larger COMPACT study12 and used identical inclusion and
exclusion criteria. The patient groups recruited had similar
demography and severity of asthma to those in the COMPACT
study. The results of the current study show very similar
clinical effects to the COMPACT study, with an improvement
in PEF and QoL in both the montelukast and budesonide
treatment groups. As in the larger COMPACT study the time
course of improvement in PEF was sustained throughout the
treatment period, strongly suggesting genuine drug effects
rather than regression to the mean. The important new
finding is that these clinical benefits were not associated
with changes in sputum markers of airway inflammation.
Our findings are consistent with the findings of earlier
studies showing that montelukast had no effect on eosino-
philic airway inflammation in patients treated with inhaled
corticosteroids.17,18 In contrast, two studies have shown
that treatment with montelukast is associated with a
significant reduction in sputum eosinophil counts in patients
with asthma treated with bronchodilators only.19,20 These
findings suggest a difference between the effects of
montelukast on eosinophilic airway inflammation in patients
on and off inhaled corticosteroids.
Complete sputum data were only available for 69% of
patients, partially because this was a multi-centre trial
involving some centres with no prior experience in induced
sputum methodology. The incomplete data are unlikely to
cause a systematic bias in the study as they were evenly
distributed between the montelukast and doubled dose
steroid groups. This does lead to a reduction in power, but
the primary approach to the analysis was descriptive rather
than hypothesis testing.
A relevant finding in the current study is that approxi-
mately two-thirds of patients with symptomatic asthma on
inhaled corticosteroids do not have a sputum eosinophil
count outside the normal range ðo2%Þ. This is consistent
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N. Barnes et al.1656with the view that there is not a simple causal relationship
between eosinophilic inflammation, asthma symptoms and
disordered lung function.21
Overall there was no evidence for a decrease in
eosinophilic inflammation with either a doubling dose of
inhaled corticosteroids or the addition of montelukast.
There are several possible explanations for these findings.
It could be that sputum eosinophilia does not capture the
anti-inflammatory effects of either high dose inhaled
steroids or the addition of a leukotriene receptor antagonist
and that alternative techniques such as bronchial biopsy or
measurement of exhaled markers of inflammation are
necessary to detect an effect. However, experience with
the anti-IL-5 monoclonal antibodies suggests that the
induced sputum eosinophil count is more responsive to
change than tissue eosinophil counts,22 suggesting that this
is not the case. It is possible that montelukast and increased
inhaled steroid strategies are affecting other functionally
important aspects of airway inflammation that are not
demonstrated by induced sputum analysis such as airway
oedema23 or the number of mast cells in airway smooth
muscle.24
Another reason for a failure overall to detect an anti-
inflammatory effect may be that the general level of
eosinophilic inflammation was so low at baseline that there
was no room for either drug to improve this. Some support
for this suggestion comes from looking at the approximately
one-third of the patients who had an eosinophil level above
the normal range ðX2:0%Þ. In this group of patients both the
addition of montelukast and an increase in the dose of
budesonide produced a small decrease in the sputum
eosinophilia which was not statistically significant, although
power to detect a difference was very low. This group of
patients were a pre-specified group described in the analysis
plan. In the absence of a placebo group it is possible that the
changes seen were due to regression to the mean. Clearly
further investigation of the subgroup with a raised eosino-
phil count would be worthwhile, although an earlier small
study suggests that montelukast treatment does not reduce
the sputum eosinophil count in patients with persistent
eosinophilic airway inflammation despite treatment with
inhaled corticosteroids.17
A secondary aim of the study was to investigate whether
there was any correlation between the baseline level of
airway inflammation measured in sputum and improvement
in clinical asthma, or changes in airway inflammation and
measures of improvement in clinical asthma. We found no
correlation between any of the baseline sputum measure-
ments or any of the changes in airway inflammation, with
short-term measures of asthma control such as PEF. This
adds to data indicating that there is little evidence for a
relationship between measures of inflammation or lung
function and symptoms in patients treated with inhaled
corticosteroids.21,24 There is, however, evidence that
persisting eosinophilia is related to risk of asthma exacer-
bation.24 The patients in the current study did not
experience a sufficient level of exacerbations to investigate
whether there was any relation between risk of exacerba-
tion and airway eosinophilia.
In conclusion the current study has confirmed the
beneficial effects of both increasing the dose of inhaled
steroid or addition of montelukast in symptomatic patients
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Figure 2 Morning peak expiratory flow (am PEF) over the 12-week treatment period, paired data (solid line ¼ budesonide 800mgþ
montelukast 10mg daily ðn ¼ 24Þ, dashed line ¼ budesonide 1600mg daily ðn ¼ 28Þ). Data represent the mean am PEF measured
before administration of study medication.
Asthma: Sptum cells and mediators 1657treated with moderate doses of inhaled steroid. It demon-
strated that despite symptomatic asthma nearly two-thirds
of patients have no measurable eosinophilic airway inflam-
mation, which adds to the growing body of evidence that the
relationship between asthmatic symptoms, disordered lung
function and airway eosinophilia is complex.Acknowledgements
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